Valuation: Apogee Therapeutics, Inc.

Market Cap 1.01TCr 874.28Cr 815.15Cr 748.84Cr 1.42TCr 96TCr 1.43TCr 9.61TCr 3.76TCr 48TCr 3.78TCr 3.7TCr 1,58600Cr P/E 2026 *
-31.1x
P/E 2027 * -24x
Enterprise Value 908.93Cr 789.22Cr 735.85Cr 675.99Cr 1.28TCr 86TCr 1.29TCr 8.68TCr 3.39TCr 43TCr 3.41TCr 3.34TCr 1,43200Cr EV / Sales 2026 *
1,000x
EV / Sales 2027 * 746x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day+0.06%
1 week+0.01%
Current month+0.07%
1 month+0.52%
3 months+60.61%
6 months+106.83%
Current year+77.78%
1 week 134.03
Extreme 134.03
134.35
1 month 133.13
Extreme 133.13
134.46
Current year 60.35
Extreme 60.35
134.46
1 year 34.34
Extreme 34.34
134.46
3 years 14.19
Extreme 14.19
134.46
5 years 14.19
Extreme 14.19
134.46
10 years 14.19
Extreme 14.19
134.46
Manager TitleAgeSince
Chief Executive Officer 36 01/09/2022
Director of Finance/CFO 60 01/01/2023
Chief Tech/Sci/R&D Officer - 01/05/2023
Director TitleAgeSince
Director/Board Member 54 22/06/2023
Director/Board Member 62 01/06/2023
Director/Board Member 36 01/06/2023
Date Insider Type Main position Quantity % Market Cap.
24/07/26 Don

Chief Financial Officer

-15,000 0.0268%
14/07/26 Don

Chief Technology Officer

-8,000 0.0143%
10/07/26 Don

Chief Executive Officer

-75,046 0.1340%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%+0.01%+260.34%+548.26% 1.01TCr
-0.68%-0.54%-2.73%+13.55% 4.82TCr
+6.03%+5.22%+420.33%+519.87% 3.88TCr
-2.21%-6.07%+24.87%+5.20% 3.84TCr
+2.94%-2.25%+6.15%+59.69% 3.49TCr
+1.98%+3.97%+13.89%+40.90% 2.92TCr
+0.31%+0.72%+32.99%+122.25% 1.6TCr
+0.47%-3.87% - - 1.6TCr
+1.59%+2.84%+4.40%+16.88% 1.35TCr
-0.98%-12.98%-4.82%-38.09% 1.22TCr
Average +1.04%-0.56%+83.93%+143.17% 2.57TCr
Weighted average by Cap. +1.31%+0.20%+86.60%+130.67%

Financials

2026 *2027 *
Net sales 90.91L 78.94L 73.6L 67.61L 1.28Cr 86Cr 1.29Cr 8.68Cr 3.39Cr 43Cr 3.41Cr 3.34Cr 143.23Cr 1.25Cr 1.09Cr 1.01Cr 92.96L 1.76Cr 118.9Cr 1.78Cr 12Cr 4.66Cr 59Cr 4.69Cr 4.59Cr 196.94Cr
Net income -32Cr -28Cr -26Cr -24Cr -45Cr -3.02TCr -45Cr -303.07Cr -118.47Cr -1.51TCr -119.24Cr -116.63Cr -5TCr -42Cr -36Cr -34Cr -31Cr -59Cr -3.96TCr -59Cr -397.48Cr -155.38Cr -1.98TCr -156.39Cr -152.96Cr -6.56TCr
Net Debt -98Cr -85Cr -79Cr -73Cr -137.77Cr -9.32TCr -139.29Cr -934.91Cr -365.47Cr -4.66TCr -367.83Cr -359.77Cr -15TCr -74Cr -64Cr -60Cr -55Cr -104.12Cr -7.04TCr -105.26Cr -706.52Cr -276.19Cr -3.52TCr -277.98Cr -271.88Cr -12TCr
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
05/26/05 $134.19 +0.06% 23,77,912
03/26/03 $134.11 +0.01% 10,59,851
31/26/31 $134.09 -0.16% 17,44,242
30/26/30 $134.30 +0.07% 8,40,599
29/26/29 $134.20 +0.02% 10,82,800
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
134.11USD
Average target price
130.53USD
Spread / Average Target
-2.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock